Strong Q1 beats guidance; CGHS tailwind masks volume deceleration risk

19.1% YoY confirmed; beats early-to-mid-teens FY27 guidance

31.0% OPM delivered, but management states will reinvest upside, not guiding higher

8.2% confirmed; exceeds guidance but partly attributable to low-base effect (fever season last year)

Confirmed; benefit will tail 2–3 more quarters only; remainder from test/geography mix

Q1 Swasthfit growth 20% range confirmed; still 27% of revenue; Tier 2/3 traction growing

Prior guidance ₹100–120 Cr; informal raise to ₹140–150 Cr for radiology centers, lab expansions. Not formally updated in call.

Prior 'early-to-mid-teens'; management now says 'chances are mid-teens' after Q1 beat. Informal, will formalize post-Q2.

Reconfirmed prior guidance. No acceleration despite strong cash position (₹1,693 Cr).

Q1 delivered 31%, but management explicitly states will reinvest and reassess. No formal guidance upgrade.

CGHS adds 2–3% at company level; benefit continues 2–3 more quarters. Rest is test/geography mix.

Too early to comment; 6–7% was guidance. Once we finish Q2, better clarity on full-year outlook. One quarter not reliable.

Pricing is a strategic lever; dependent on competition, cost pressures. Planned for H2, not H1. Will reassess.

Rural program is health initiative for NCD burden; tests 110K patients so far. Volume growth is across all geographies, not restricted to one.

Q1 ahead of expectations. After first half, more confident on forecast. Chances are toward mid-teens rather than early-teens.

Swasthfit growing at 20% this quarter; aim to sustain. Wider acceptance in Tier 2/3.

Don't disclose genomics separately; <5% of portfolio. Focused on that area for cancer diagnostics.

CGHS 2–3%; rest is mix of test (specialized higher-realization) and geography (Delhi NCR is higher-realization). Hard to itemize.

Neuome is startup on diagnostic supply chain; if innovations fructify, huge operational benefit. Direct benefit to operations, not new venture.

International is longer-term project. No near-term contribution change. Once we learn to run intl ops, may set targets for 4–5 years out.

Like last year, 12–15 labs. Also pilot 1–2 radiology centers outside Delhi NCR in Tier 2 towns; 3–4 total radiology centers.

Post-LIMS integration, Suburban business turning around, close to double-digit growth. Investing in stores, radiology, collection network; expect trajectory to improve.

Pillar is scientific excellence, not just new tests. Ability to solve complex cases drives clinician choice. Mix of in-house and partnership (intl partnerships).

Contribution <5%; unlikely to meaningfully exceed that in next 5 years.

Swasthfit 27% revenue, grew 20% (in line with 19% overall). Contribution flat because growth rates matched. Other portfolio (73%) has specialized high-realization tests also growing.

Reclassification from employee to logistics cost; like-to-like prior quarter also reclassified. No structural change.

Growth is structural across all geographies. No differential trigger identified yet; need few more quarters to get clarity.

Don't jump to conclusion. Q2/Q3 last year had fever-season impact on low numbers. Need cycle to run; haven't entered fever season this year.

CGHS higher realization will pass-through to margins for 1–2 more quarters.

Always reinvest for future growth. Clearer decision after Q2, visibility on annual trajectory. Lean toward investing more for growth.

Swasthfit contribution flattened vs last year. But specialized tests and high-realization geographies are levers. Realization improvement likely for next few quarters.

B2C at 75%, consistent this quarter. 75:25 mix is good; growing both channels, aiming to retain.

Not calculating Suburban profitability separately; post-liquidation, backend merged, interoperability achieved.

No industry-level data to pick out. Broad-based improvement visible. Competition always intense, likely to stay intense.

Not seeing structural price change in last few quarters. Competitive intensity or pricing remains neither favorable nor unfavorable.

No rural-urban divide. Across-geography good growth.

Tier 3 and below is 39% of revenue (last FY).

CGHS released common price list for country. Some price cuts by geography type, but applied uniformly.

Sovaaka is high-end premium diagnostics-wellness portfolio. Stabilizing first center, fine-tuning model. Still in learning phase.

3–5 year horizon. Steps to understand markets (Africa, Middle East, CIS, Southeast Asia) to run local businesses. Near-term learning, future build-out.

Major use: M&As in West/South India (larger assets). Capex on high-end radiology. CapEx ₹140–150 Cr.

Q1 at 19.1% beat. Management said 'chances mid-teens' after Q1; will formalize post-Q2. CGHS adds 2–3% temporary benefit.

Q1 delivered 31%, but mgmt explicitly reinvesting upside. No formal upgrade. Will reassess Q2. CGHS flow-through to margins 1–2 quarters only.

Confirmed at end of call. 12–15 lab additions + 3–4 radiology centers (pilot Tier 2 outside Delhi NCR). Maintenance + growth capex.

2–3% of Q1 growth from CGHS; benefit ends in 2–3 quarters. If organic growth without CGHS <16%, guidance will be missed.

8.2% patient volume beats 6–7% guidance. Management attributes partly to low fever-season base last year (Q2–Q3). If 8% is peak, growth resets to 6–7% H2.

Q1 EBITDA 31% vs 27–28% guidance. Management stated will reinvest upside, not formally upgrade guidance. If reinvestment is aggressive, FY27 margin could compress back to 27–28%.

Management states competitive intensity 'always intense' and unlikely to reduce. Price hikes deferred to H2 pending reassessment. Industry still consolidating; hospital-based labs entering.

Ghana (Sunshine), Dubai subsidiary, Neuome stake all framed as 3–5 year learning projects. International <5% revenue, unlikely to exceed 5% for ≥5 years. If execution falters, cash could be stranded.